We have recently reported the activation of a new oncogene in human papillary thyroid carcinomas. This oncogene, papillary thyroid carcinoma (PTC), is a novel rearranged version of the ret tyrosine-kinase protooncogene. Thyroid neoplasms include a broad spectrum of malignant tumors, ranging from well-differentiated tumors to undifferentiated anaplastic carcinomas. To determine the frequency of ret oncogene activation, we analyzed 286 cases of human thyroid tumors of diverse histologic types. We found the presence of an activated form of the ret oncogene in 33 (19%) of 177 papillary carcinomas. By contrast, none of the other 109 thyroid tumors, which included 37 follicular, 15 anaplastic, and 18 medullary carcinomas, and 34 benign lesions, showed ret activation. (J. Clin. Invest. 1992. 89:1517-1522
Introduction
There is growing evidence that tumor development and progression may result from a series of genetic alterations that affect the normal mechanisms controlling cell proliferation (1) . Molecular events that have been identified include inactivation of tumor-suppressor genes (2) , as well as activating mutations of cellular protooncogenes (3) . In some cases, specific oncogenes are altered in specific tumors. Thus, the N-myc and cerb-B2/neu oncogenes are amplified in neuroblastomas (4) and in breast carcinomas (5) , respectively. Similarly, c-myc and cablare involved in the chromosomal translocations which characterize Burkitt's lymphoma and chronic myelogenous leukemia (3), respectively. Moreover, there is some evidence suggesting a specificity for activation of particular ras gene family members in some forms of cancer: e.g., K-ras in lung, colon, and pancreas carcinomas (6) (7) (8) , and N-ras in acute myeloid leukemia (9) .
The thyroid provides an attractive model to study the steps that are involved in the neoplastic process. Most thyroid neoplasms originate from a single cell type, the thyroid follicular cell. However, they comprise a broad spectrum oftumors with different phenotypic characteristics and variable biological and clinical behavior: i.e., from the benign colloid adenomas, through the slowly progressive differentiated papillary and follicular carcinomas, to the invariably fatal anaplastic carcinomas (10) . Papillary and follicular carcinomas are considered to be two different biological entities. Typically, papillary carcinoma is multifocal. It generally metastasizes to regional lymph nodes, and has been associated with previous radiation exposure. Conversely, follicular carcinoma is solitary and encapsulated. It invades blood vessels and spreads often to bones; its highest incidence has been reported from endemic goitrous areas (10) . It seems probable that the differences observed in biological behavior could be explained by the involvement of different genetic events in the pathogenesis of these two differing follicular cell-derived malignancies.
We have recently demonstrated the frequent activation ofa new oncogene in human papillary thyroid carcinomas (1 1-13). We have shown that this oncogene, named papillary thyroid carcinoma (PTC),I is the product of the recombination of the tyrosine-kinase domain of the ret protooncogene with a thus far uncharacterized gene that we have named H4 (13) . In addition, we have observed that an inversion (l0)(ql1.2-q2 1) is present in a significant number ofpapillary thyroid carcinomas (14) . The ret and H4 genes are both localized on the long arm of the chromosome 10 (15) (16) (17) , and we have demonstrated that at least in four cases, the inversion on chromosome 10 determines their fusion (1 
7a).
To confirm the frequency of activation of ret in papillary tumors in a wider collection of samples, and to ascertain what role ret activation may play in the pathogenesis ofnonpapillary thyroid tumors, we have analyzed 286 human thyroid neoplasms collected at the Mayo Clinic, Rochester, Minnesota, at the Hospitals of Lyon, France, at the Istituto Nazionale Tumori of Milan, and at the II Medical School ofNaples, Italy. In this study we demonstrate that ret oncogene is frequently activated only in the papillary histotype of thyroid carcinomas. From these findings, we would suggest that ret activation may represent a specific genetic event that may be of value in the differential diagnosis of papillary thyroid cancer in man. (13) . Above the maps are illustrated the DNA probes used in this study. They correspond to the probes indicated in Fig. 1 RNA analysis and polymerase chain reaction (PCR). RNA extraction was performed, as previously described (19). The RNA amplification was done following the method described by E. S. Kawasaki (20) 
Results
Southern blot analysis. The ret protooncogene encodes a protein structurally related to transmembrane receptors with a cytoplasmic tyrosine-kinase domain (21) (22) (23) . We have demonstrated that the truncation of the NH2-terminal region leads to its activation in thyroid papillary carcinomas. This rearrangement occurs in an intronic sequence that lies between the TK and the transmembrane-encoding domain of the ret protooncogene, and it is possible to detect this rearrangement by Southern blot analysis of the tumor DNA (13) . Fig. 1 shows a schematic representation ofthe genomic restriction maps ofret and H4, and of the rearrangements between the two genes previously reported (13). Here, we report the analysis of 286 neoplastic thyroid samples for ret activation. This analysis has been performed by probing Southern blots with a 1-kbp BglII-BamHI DNA fragment. This fragment is able to identify the region within the ret gene where rearrangement occurs (Probe 7 of Fig. 1) (13) . This probe hybridizes to a 6.3-kbp EcoRI, a 3.7-kbp BamHI, and a 9.3-kbp HindIII restriction fragment in normal human DNA (see map on Fig. 2) . We found that 33 (11.5%) out of 286 samples showed adjunctive rearranged bands, and this result was demonstrable with at least three different restriction enzymes (examples are in Figs. 2 and 3) . In some cases, the rearranged band had a decreased intensity with respect to the normal one (for example, lane 10, Fig. 2 ). This is most likely due to contamination of the tumoral specimen by normal surrounding tissue. The possibility that the rearrangement might involve only a fraction ofthe neoplastic cells is currently under investigation by using the in situ RNA hybridization technique.
The rearrangement was specific for the papillary histotype; it was present in 11 out of 65 papillary samples (16.9%) collected at the Mayo Clinic, 8 out of 70 (11.4%) from Lyon, and 14 out of 42 (33.3%) from Milan. We did not find any rearrangement in the 37 follicular, 15 anaplastic, and 18 medullary carcinomas, nor in the 34 benign lesions that we have analyzed (Table I) .
Transfection assay. We evaluated the transforming activity of the 14 samples collected at the Istituto Nazionale Tumori of Milan which already scored positive for ret rearrangement. All the samples, tested by the standard focus formation assay on NIH/3T3 cells, gave rise to transformed foci in 2-3 wk (Table  II) . Also, the available metastases of the ret-positive tumors scored positive (Table II) . Hybridization ofthe DNA extracted from the primary foci of transformed NIH/3T3 cells with retspecific probes allowed us to conclude that the transferred oncogene was actually an activated version of ret (data not shown). We also transfected the DNA extracted from nine follicular tumors; none gave rise to transformed foci (Table II) . Further characterization of gene rearrangement. We had previously reported that when tumors carrying an activated version of ret were probed with a NH2-terminal protoret-speci- fic sequence, a rearranged band was also detectable. This suggests that the chromosomal event leading to ret activation should not involve deletion of its NH2-terminal encoding domain (13) . Subsequently, we have demonstrated that an inversion (10) (q 11.2-21) determined the H4-ret fusion in at least four cases of papillary thyroid carcinoma (1 7a). In the present study, we found that many ofthe samples also showed a similar mechanism. In fact, 10/11 samples from Mayo, 5/8 from Lyon, and 9/9 from Milan showed rearranged bands when probed with a 5'-terminal 1.8-kbp ret-specific BamHI DNA fragment (probe 12 of Fig. 1 ) (Examples are shown in Fig. 4) . The PTC oncogene that we had isolated from papillary thyroid carcinomas by means ofthe transfection assay was shown to be the product ofa fusion between a truncated ret gene and a novel sequence that we named H4 (13) . We demonstrated that the truncation of the H4 gene could occur in different points over a sequence of several thousand base pairs ( Fig. 1) (13) . Thus, the analysis of H4 involvement has been performed by using different probes (shown in Fig. 1 ) from Alu-free regions of the H4 gene (probes 2, 8, 9, 10, 11, 3, of Fig. 1) (13) . Fig. 5 shows the H4 gene rearrangement in the sample 14 from Lyon (probe 2 ofFig. 1) (13) . We have shown H4 rearrangement also in one other sample that was collected at the Mayo Clinic (sample D ofFig. 2) and cytogenetically showed a chromosome lOq inversion (14, 1 7a) . Moreover, 7 out of the 14 samples which scored positive in the transfection assay showed H4 involvement, since in these cases the primary NIH/3T3 foci contained H4-specific sequences (Table II) .
RNA and PCR analysis. We have previously shown that ret rearrangement leading to PTC formation gives rise to truncated transcripts. The H4 promoter, which fuses to ret, is able to drive its expression in the thyroid tumor that carries the rearrangement. To increase the possibility ofdetecting the PTC formation, and to verify H4 involvement in the cases in which apparently by the Southern blot analysis H4 was not rearranged, we performed a PCR analysis on the RNA extracted -from five ret-rearranged tumors. We copied 5 Mg of tumoral RNA by using reverse transcriptase and an antisense 18-bases long 3' ret-specific oligonucleotide primer. We amplified the resultant cDNA with the same 3' primer and a sense H4-specific 18-bases oligomer. An amplified 363-bp long fragment indicated the presence of a fused H4-ret transcript (i.e., activated PTC). The correct sized fragment was found in samples 10, 14, and 53 from Lyon, but not in samples 9 (Fig. 6) and 55 (not shown). Thus, in samples 10, 14, and 53, ret was fused to H4; conversely in the samples 9 and 55, the rearrangement of the ret protooncogene probably involved a gene distinct from H4.
Discussion
The identification of the nature of the genetic mutations in thyroid neoplasms, and the assessment of their prevalence in the various tumor phenotypes, is critical to an understanding -363bp - Figure 6 . Expression in papillary thyroid carcinomas of a fused H4-ret transcript. PCR analysis on the RNA extracted from four papillary carcinomas collected at the Hospitals of Lyon. 5 tig of total RNA were reverse transcribed using an antisense ret-specific oligonucleotide, and amplified using the same oligo together with an H4-specific amplimer. 1/10 of the product of the amplification was subjected to electrophoretic separation on a 2% agarose gel. of their pathogenesis. Different genetic events may occur to determine the different phenotypic characteristics of thyroid neoplasms, such as the ability to invade the lymphatics (papillary) or the blood vessels (follicular), or the propensity to become dedifferentiated (anaplastic) .
We previously demonstrated the activation of the ret oncogene in papillary carcinomas (12, 13) . To date, the ret-transforming gene has been found activated in vivo only in thyroid carcinomas (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] and in a papillary thyroid carcinoma cell line (24) . Previously described rearrangements of the ret oncogene were found to have occurred in vitro during the transfection procedure (25) (26) (27) Recently, Ishizaka et al. (29) published the detection of an activated ret (PTC) in 1 out of 11 thyroid papillary carcinomas, but also in 4 out of 19 follicular adenomas and in one of two adenomatous goiters. In the adenomas, however, the activation of ret was detected only in some regions of the tumors. They do not report any analysis of nonpapillary malignant tumors. Since the prevalence of occult thyroid carcinomas in the Japanese population is high, it is possible that the PTC-positive cases of follicular adenomas and adenomatous goiter could reflect a minor population of cancerous cells, as the authors suggest in their discussion.
We also noted a difference in the frequency of ret activation in different geographic areas, ranging from 11% in the French samples to 33% in the Italian samples. The U. S. tumors had an intermediate frequency of 17%. This may suggest the involvement of different genetic or environmental factors in these three areas. The recent finding of high rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area (30) , and the differences detected in the patterns of ras mutation between radiation-associated and spontaneous human thyroid carcinomas (31) seem to support such suggestion. It is noteworthy that only one of the patients positive for ret activation in this study, had a prior documented radiation exposure.
We have also been able to demonstrate that the H4 gene was involved in ret activation in 11 out of 33 ret rearranged samples. We demonstrated this involvement in two cases by Southern blot analysis (samples 14 and D) , in three cases by PCR analysis (samples 10, 53, and again, 14) , and in seven cases (Milan samples) by the transfection assay. We cannot exclude, however, that H4 may be involved in the remaining cases because we did not have enough RNA and DNA to perform PCR or transfection assays, respectively, in the apparently negative samples. In at least 5 of these 22 cases we have conclusively demonstrated that ret is not fused to H4, and still other uncharacterized genes may be involved in the rearrangement. Interestingly, cytogenetic studies of papillary carcinoma have demonstrated that the region where ret is mapped (10q 1 1.2) is also involved in translocations with other chromosomes (14) .
In 24 of 33 ret-rearranged cases, the 5'terminal region ofthe ret gene (extracellular and transmembrane encoding region) was not deleted, but was present rather in a rearranged status, similar to previously described cases (13) .
There still remain major unanswered questions about the manner in which thyroid tumors evolve, and the molecular events that determine whether a tumor behaves either as a differentiated papillary/follicular or as a dedifferentiated anaplastic one. Other genetic alterations are frequently detected in thyroid tumors and include mutations involving ras genes. However, the published studies on ras oncogene involvement (30) (31) (32) (33) (34) (35) (36) indicate a significant heterogeneity among the results obtained by different groups. Whereas ras point mutations are present with an about equivalent frequency in both benign and malignant thyroid tumors, the same conclusion is not readily established when the follicular and papillary types are compared. We have previously demonstrated that the oncogene trk, belonging to the tyrosine kinase family, is also frequently (about 10%) activated in papillary carcinomas (12) , and recently, Suarez et al. (37) observed gsp mutations in -10% of differentiated thyroid carcinomas. In addition, allelic loss studies of chromosome 3 and 10 have demonstrated differences between papillary and follicular carcinomas (38 indicate that other somatic mutations should be considered to explain the differing behavior patterns exhibited by different thyroid tumor types. However, from our studies we would suggest that ret activation represents an important and apparently specific genetic event in the development of human papillary thyroid carcinoma.
